Retail Investors Who Have a Significant Stake Must Be Disappointed Along With Institutions After Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Market Cap Dropped by CN¥694m
Retail Investors Who Have a Significant Stake Must Be Disappointed Along With Institutions After Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Market Cap Dropped by CN¥694m
Key Insights
主要见解
- Henan Lingrui Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
- 45% of the business is held by the top 25 shareholders
- Institutions own 25% of Henan Lingrui Pharmaceutical
- 河南羚锐制药的重要零售投资者持股表明,其关键决策受较大公众股东的影响。
- 前25大股东占45%的业务。
- 机构持有河南羚锐制药25%的股份。
A look at the shareholders of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) can tell us which group is most powerful. The group holding the most number of shares in the company, around 52% to be precise, is retail investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
通过了解河南羚锐制药股东情况,我们可以了解到哪个群体最为强大。拥有公司最多股份的群体,具体来说是约52%的普通股股东,受益于股票上涨并承受股票下跌风险最高。
Following a 5.0% decrease in the stock price last week, retail investors suffered the most losses, but institutions who own 25% stock also took a hit.
上周股价下跌5.0%,零售投资者遭受了最大的损失,但持有25%股票的机构投资者也受到了打击。
Let's take a closer look to see what the different types of shareholders can tell us about Henan Lingrui Pharmaceutical.
让我们仔细看看不同类型的股东对河南羚锐制药的影响。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240717/0-4a6778634903876bbee9df249aceb229-0-4fc182155a9d47bd3b60b529a9a09a36.png/big)
What Does The Institutional Ownership Tell Us About Henan Lingrui Pharmaceutical?
机构持股信息提示我们有机构投资者持有河南羚锐制药的股份,并且他们持有公司相当大的股份。这意味着为这些机构工作的分析师们看好这只股票。但是与其他人一样,他们也可能出错。如果两位大型机构投资者同时试图出售一只股票,那么大幅股价下跌并不罕见。所以有必要查看河南羚锐制药过去的盈利情况(如下所示)。当然,还要考虑其他因素。
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构衡量其业绩的标准是一个近似于当地市场的指数。因此,他们通常更加关注包括在主要指数中的公司。
We can see that Henan Lingrui Pharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Henan Lingrui Pharmaceutical, (below). Of course, keep in mind that there are other factors to consider, too.
我们可以看到,河南羚锐制药确实有机构投资者,并且他们持有公司相当大的股份。这意味着为这些机构投资者工作的分析师们看好这只股票。但是与其他人一样,他们也可能出错。如果两位大型机构投资者同时试图出售一只股票,那么大幅股价下跌并不罕见。所以有必要查看河南羚锐制药过去的盈利情况(如下所示)。当然,还要考虑其他因素。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240717/0-4a6778634903876bbee9df249aceb229-1-0f7d00a78199cdf862d57b5e3f625776.png/big)
Hedge funds don't have many shares in Henan Lingrui Pharmaceutical. Looking at our data, we can see that the largest shareholder is Henan Lingrui Group Co., Ltd. with 22% of shares outstanding. With 4.2% and 4.1% of the shares outstanding respectively, National Council for Social Security Fund and GF Fund Management Co., Ltd. are the second and third largest shareholders. Additionally, the company's CEO Wei Xiong directly holds 0.6% of the total shares outstanding.
对于河南羚锐制药,对冲基金持有的股份并不多。从我们的数据来看,拥有公司22%流通股的河南羚锐集团有限公司是最大的股东。第二大股东是占流通股的4.2%的全国社会保障基金和占流通股的4.1%的广发基金管理有限公司。此外,该公司的首席执行官熊薇直接持有总流通股的0.6%。
On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.
经过我们的所有权数据研究,我们发现前25位股东共同拥有不到50%的股份,表明没有任何个人拥有多数利益。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.
虽然研究公司的机构持股可以增加您的研究价值,但研究分析师的建议以加深对股票预期表现的全面了解也是一个好习惯。虽然有部分分析师的覆盖,但该公司可能没有受到广泛的关注。因此,在未来可能会受到更多关注。
Insider Ownership Of Henan Lingrui Pharmaceutical
河南羚锐制药的内部持股情况
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
内部人员的定义在不同国家可能会稍有不同,但董事会成员始终算入其中。公司管理负责经营业务,但即使首席执行官是董事会成员,他或她也必须对董事会负责。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部人士持股是一件好事。但是,在某些情况下,它会使其他股东更难以对董事会的决定进行问责。
We can report that insiders do own shares in Henan Lingrui Pharmaceutical Co., Ltd.. This is a big company, so it is good to see this level of alignment. Insiders own CN¥185m worth of shares (at current prices). Most would say this shows alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.
我们可以报告说,内部人员确实持有河南羚锐制药有限公司的股份。这是一家大公司,所以看到这种程度的一致性是好的。内部人员拥有现价值1,8500万元人民币的股份。大多数人会说这显示了股东和董事会之间的利益一致性。不过,如果这些内部人员一直在出售股份,最好还是检查一下。
General Public Ownership
一般大众所有权
The general public, who are usually individual investors, hold a substantial 52% stake in Henan Lingrui Pharmaceutical, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.
普通大众(通常是个人投资者)持有河南羚锐制药的52%股份,这表明它是一只相当受欢迎的股票。这种持股规模为普通大众投资者提供了一定的集体力量。他们可以并且可能会在执行薪酬、股息政策和拟议业务收购决策方面发挥影响力。
Private Company Ownership
私有公司的所有权
Our data indicates that Private Companies hold 22%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
我发现看一家公司确切的所有者非常有趣。但是,为了真正获得洞察力,我们需要考虑其他信息。例如,我们已经确定了Transwarp Technology (Shanghai)有限公司的2个警告信号,您应该了解。
Next Steps:
下一步:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for Henan Lingrui Pharmaceutical that you should be aware of.
我发现看到一个公司的所有者是谁非常有趣。但要获得真正的见解,我们还需要考虑其他信息。例如,我们已经确定了河南羚锐制药的一个警告信号,您应该知道。
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
最终,未来最重要。您可以在这份关于该公司分析师预测的免费报告中获取有关信息。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。